Sentry Study: Raman Spectroscopy on Ex Vivo Lungs

Lung Cancer Clinical Trial

Official title: A Prospective Pre-Market Proof-of-Concept Study for Ex Vivo Raman Spectroscopy Measurements on Excised Lung Tissue With the Sentry System

Status Terminated

Clinical Trial Summary

In this proof-of-concept, ex vivo study, the study team will investigate whether Raman spectroscopy technology is a good candidate for the identification of cancerous lung tissue.

Clinical Trial Description

Lung cancer is the most prevalent form of cancer worldwide and the leading cause of cancer-related deaths. Despite recent advances in treatment, the five-year survival rate remains below 25% [State of Lung Cancer Report 2021,American Lung Association. This is largely due to the fact that most patients are diagnosed only at advanced stages of the disease when treatments are ineffective and the prognosis is poor. The National Lung Screening Trial demonstrated the utility of lung cancer screening by low-dose computed tomography (CT) to improve early detection\ and reduce lung cancer-related mortality by 20%. Earlier detection of lung lesions in turn created an increased need for better early diagnosis modalities. Reveal Surgical is developing medical devices for tissue characterization based on Raman spectroscopy technology. In this proof-of-concept, ex vivo study, the study team will investigate whether Raman spectroscopy technology is a good candidate for the identification of cancerous lung tissue. ;

Related Conditions & MeSH terms

• Lung Cancer

• NCT number: NCT05790226
• Study type: Interventional
• Source: University Health Network, Toronto
• Status: Terminated
• Phase: N/A
• Start date: January 9, 2023
• Completion date: November 6, 2023